- EditCo’s robust, HiBiT-tagged CRISPR knock-ins transform cells into powerful biosensors — perfect for drug discovery, cell-based assays, and protein quantification.
- Through this partnership, EditCo Bio expands its capabilities by incorporating Promega’s proprietary bioluminescent and protein-labeling technologies into its CRISPR-engineered cell lines, ensuring precise gene edits with functional validation.
REDWOOD CITY, CA, April 22, 2025 – EditCo Bio, Inc. has announced a strategic licensing
agreement with Promega Corporation, granting EditCo access to Promega’s HiBiT, HaloTag®,
and NanoLuc® technologies. These advanced protein-tagging and bioluminescent detection
systems will be integrated into EditCo’s CRISPR knock-in services. This collaboration
strengthens EditCo’s position as a leader in engineered cell solutions by enabling researchers
to generate highly reproducible and reliable gene-edited models for a wide range of
applications.
Through this agreement, EditCo will not only facilitate precise genomic knock-ins but also offer
functional validation services, ensuring that engineered cells maintain proper protein
expression, stability, and activity. These capabilities empower researchers with cell models
optimized for mechanistic studies, drug screening, and other advanced applications requiring
quantitative protein analysis.
“Our collaboration with Promega underscores EditCo’s commitment to delivering industry-
leading CRISPR-engineered cells that go beyond genetic modification by incorporating
functional validation,” said Travis Maures, PhD, Chief Scientific Officer at EditCo Bio. “By
integrating HiBiT, HaloTag, and NanoLuc into our knock-in workflows, we provide researchers
with powerful tools to track protein expression, interactions, and activity with high sensitivity and
accuracy. This partnership will accelerate discoveries in functional genomics, drug
development, and therapeutic research.”
“This agreement accelerates scientific innovation by providing researchers with
advanced cellular models engineered for precise functional analysis,” says Tom Livelli,
Promega Vice President, Life Sciences. “Leveraging these technologies enables
scientists to probe protein dynamics directly within living cells, empowering deeper
insights into complex biological mechanisms.”
Expanding Functional Assays with HiBiT, HaloTag, and NanoLuc
- HiBiT: A small bioluminescent peptide tag that enables sensitive, quantitative analysis of
protein expression and interactions in live cells. - HaloTag: A versatile protein labeling system that allows covalent attachment of
fluorescent and bioluminescent probes for imaging, protein interaction studies, and
biochemical assays. - NanoLuc: A highly sensitive luciferase enzyme that provides exceptional
bioluminescence for real-time monitoring of cellular and molecular processes.
EditCo’s licensing agreement with Promega enables the development of custom-engineered cell
lines incorporating these technologies exclusively for research use. Researchers can leverage
these advanced tools to create reliable and reproducible cellular models with functional
validation, streamlining experimental workflows and increasing data confidence.
For more details on EditCo’s CRISPR Knock-in Services featuring HiBiT, HaloTag, and
NanoLuc, visit www.EditCo.bio.
About EditCo Bio, Inc.
EditCo Bio is a leader in engineered cell solutions, offering high-quality, functionally validated
CRISPR-edited cell lines. With a strong foundation in CRISPR genome engineering, EditCo Bio
provides researchers with precise, reproducible, and scalable gene-editing services to advance
discoveries in cell and gene therapy, drug development, and basic research.
About Promega Corporation
Promega Corporation is a global leader in life science technologies, specializing in reagents and
integrated systems for nucleic acid and protein analysis. Its proprietary technologies, including
HaloTag, NanoLuc, and HiBiT, are widely used in pharmaceutical, biotechnology, and academic
research for applications in drug discovery, molecular biology, and functional genomics.
Read more on BusinessWire.
Media Contacts:
Lindsey Wolf
pr@editco.bio
Anthony Petrucci
anthony@bioscribe.com
